ALPN
Closed
Alpine Immune Sciences Inc
64.97
+0.01 (+0.02%)
Last Update: 20 May 2024 16:30:00
Yesterday: 64.96
Day's Range: 64.97 - 64.97
Send
sign up or login to leave a comment!
When Written:
7.72
Alpine Immune Sciences Inc. is a clinical-stage biopharmaceutical company that develops therapies for cancer and autoimmune diseases. The company's proprietary technology platform, called Variant Immunoglobulin Domain (vIgD), enables the discovery and development of multifunctional immunotherapies that can address multiple targets simultaneously.
Alpine's lead product candidate, ALPN-101, is a dual ICOS/CD28 antagonist that is being developed for the treatment of autoimmune and inflammatory diseases. The company is also developing a pipeline of other vIgD-based drug candidates for the treatment of cancer and autoimmune diseases.
Alpine Immune Sciences was founded in 2015 and is headquartered in Seattle, Washington. The company went public in 2017 and is traded on the NASDAQ stock exchange under the ticker symbol "ALPN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Alpine's lead product candidate, ALPN-101, is a dual ICOS/CD28 antagonist that is being developed for the treatment of autoimmune and inflammatory diseases. The company is also developing a pipeline of other vIgD-based drug candidates for the treatment of cancer and autoimmune diseases.
Alpine Immune Sciences was founded in 2015 and is headquartered in Seattle, Washington. The company went public in 2017 and is traded on the NASDAQ stock exchange under the ticker symbol "ALPN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








